Blue test tubes arranged in a line, disappearing into the background

Drug news

DepoMed to market Cambia for Migraine in US

Read time: 1 mins

Last updated:19th Dec 2013

Published:19th Dec 2013

Source: Pharmawand

Depomed, Inc. announced that it has acquired the United States rights to Cambia (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million. In addition, Depomed may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones. Cambia is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of Migraine attacks with or without aura in adults 18 years of age or older.Tribute Pharma has rights in Canada.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Filing at FDA for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for approval of a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT

1 mins

Drug news

Gilead Sciences signs royalty-free voluntary licenses with six generic manufacturers for lenacapavir for HIV prevention

Gilead Sciences, Inc. announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries

1 min

Drug news

Eton Pharmaceuticals to acquire Increlex (mecasermin injection) from Ipsen S.A to treat severe IGF-1 deficiency

Eton Pharmaceuticals, Inc., announced that it has entered into an asset purchase agreement to acquire Increlex (mecasermin injection) from Ipsen S.A. The acquisition is expected to close near year-end 2024

1 min

See all news